IncellDx Awarded Patent for Use of CCR5 Antagonist Maraviroc in Treatment of COVID-19

IncellDx today announced it has been granted U.S. Patent No. 11,180, 491 by the U.S. Patent and Trademark Office (“USPTO”) for methods of treating coronaviruses including COVID-19 (the “Patent”). This patent underwent expedited review under the USPTO’s COVID-19 Prioritized Examination Pilot Program.